



Anteo Diagnostics (ASX:ADO)

Annual General Meeting

10th November 2014

Welcome

The Surface Science Company

MEETING FORMAT



- ☐ Introductions
- ☐ Formal Resolutions
- ☐ CEO Report
- ☐ Other Business
- ☐ Meeting Close

Introductions

Anteo Diagnostics Limited – Present

- ☐ Mark Bouris– Non Executive Chairman
- ☐ Geoff Cumming – CEO
- ☐ Richard Martin – Executive Director
- ☐ Sandra Andersen – Non Executive Director
- ☐ John Hurrell – Non Executive Director

Grant Thornton

- ☐ Matthew Bell – Partner

Formal Resolutions



Resolution 1: Adoption of Directors' Remuneration Report

Resolution 2: Re- Election of Director (Mr Richard Martin)

Resolution 3: Approval of 10% Placement Capacity

Resolution 4: Issue of Securities under Executive/Employee Share Plan

Resolution 5: Issue of 5,000,000 Options (Mr Mark Bouris)

Resolution 6: Issue of 6,000,000 Options (Mr Richard Martin)

Resolution 7: Issue of 3,000,000 Options (Ms Sandra Andersen)

Resolution 8: Issue of 3,000,000 Options (Dr John Hurrell)

RESOLUTIONS – PROXY COUNT

	Description	For	Against	Open	Excluded	Abstain	Totals
Resolution 1	Adoption of Directors' Remuneration Report	215,294,159	3,717,929	20,000	17,500,000	2,432,978	238,965,066
Resolution 2	Re- Election of Director (Mr Richard Martin)	222,925,455	8,059,713	5,995,120	0	1,984,778	238,965,066
Resolution 3	Approval of 10% Placement Capacity	208,745,197	20,758,167	9,249,404	0	212,298	238,965,066
Resolution 4	Issue of Securities under Executive/Employee Share Plan	202,329,654	6,663,010	9,164,204	17,500,000	3,308,198	238,965,066
Resolution 5	Issue of 5,000,000 Options (Mr Mark Bouris)	200,766,002	9,858,951	8,571,904	17,500,000	2,268,209	238,965,066
Resolution 6	Issue of 6,000,000 Options (Mr Richard Martin)	82,007,782	15,941,351	8,571,904	130,176,320	2,267,709	238,965,066
Resolution 7	Issue of 3,000,000 Options (Ms Sandra Andersen)	197,418,502	13,206,451	8,571,904	17,500,000	2,268,209	238,965,066
Resolution 8	Issue of 3,000,000 Options (Dr John Hurrell)	200,585,202	10,039,751	8,571,904	17,500,000	2,268,209	238,965,066



Anteo Diagnostics (ASX:ADO)

Annual General Meeting

CEO UPDATE

The Surface Science Company

2014 Review

- ***Commercialisation***
- ***Technical Development***
- ***Internal Skill Set - Personnel***
- ***Corporate Activities***



Commercialisation

Headline Projects

- BBI
 - Achieved Phase 3 goals
 - Require better sensitivity
- POC 1
 - Successful delivery
 - Expanded scope of study

AMG Products

- Maturity recognition with customers
- Broad interest – tier 1 companies
- Delivering new product per quarter



Commercialisation

Global Presence

- Permanent BD capability in 3 time zones
 - Tina - Europe
 - Josh - Americas
 - Rachel – Asia Pacific

Paid Research & Collaboration

Expanding demands

- Diagnostics
 - Particles
 - Plates
 - Plastics and other surfaces
- Separations – magnetic particles
- Medical products – coatings
- Industrial - silica

Commercialisation: New elements and an extended asset base

Technical Development

New Mix&Go Formulations

- Solidify short-term opportunities
- Open up full spectrum of uses
- Reconfirm concepts upon which Mix&Go is founded

2012

R & d

Moved from Research to Production Capability

- Base Mix&Go components
- End products
- Developed 'know how' that further protects patents

2014

r & D

The Surface You Want on the Surface You Have


Expanded Capability: Mix&Go now offers optimal results on both Hydrophilic & Hydrophobic Surfaces

Technical Development

Signal Amplification

- Here & now extending life and utility of lateral flow devices
- Generally applicable to assays

Application Diversity



Technical Trifecta: expanded technology base, more applications, addresses target markets.

Internal Skill Set (Personnel)

New People with the Expertise and Experience to Expand

- Manufacture desired Mix&Go
 - From base components
 - For specific purposes
- Production capability
- IVD & POC depth to R&D team especially lateral flow
- Techno-commercial skill at tier 1 IVD level

Ability to capably address different surface types used in a broad array of systems

Developed robust internal administration infrastructure and quality control

Implementation: Right People, Right Place, Right Time.

Corporate Perspective

Operational Subsidiary Change of Name Bio-Layer is now Anteo Technologies

- To better reflect our brand's product, patents & potential
- Avoids market perception of 'just diagnostics'

Build Capability and Asset Base

- Depth and breadth of products
- Core company skill sets




Corporate Perspective

Strategic outlook: control destiny

- Placement
 - Financial security
 - Opportunity to build asset base and capability
- Own AMG product range

Minimise Timeframes to Business Goals

- Engaged advisor
- Searching alternatives (incl M&A)



Commercial Value from Patented Technology

Thank you very much for your attendance today.

